John Treace Acquires 5,000 Shares of Treace Medical Concepts (NASDAQ:TMCI) Stock

Treace Medical Concepts, Inc. (NASDAQ:TMCI) CEO John Treace acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were purchased at an average price of $4.35 per share, with a total value of $21,750.00. Following the acquisition, the chief executive officer owned 7,393,383 shares of the company’s stock, valued at approximately $32,161,216.05. This trade represents a 0.07% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Treace Medical Concepts Trading Up 0.7%

TMCI traded up $0.03 during mid-day trading on Monday, hitting $4.37. The stock had a trading volume of 330,428 shares, compared to its average volume of 741,496. The stock’s fifty day simple moving average is $4.35 and its 200-day simple moving average is $2.89. The firm has a market capitalization of $284.20 million, a price-to-earnings ratio of -4.70 and a beta of 1.37. Treace Medical Concepts, Inc. has a 1-year low of $1.17 and a 1-year high of $7.78. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.90 and a quick ratio of 1.95.

Treace Medical Concepts (NASDAQ:TMCI) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.06. Treace Medical Concepts had a negative return on equity of 71.37% and a negative net margin of 28.99%.The business had revenue of $45.38 million for the quarter, compared to analysts’ expectations of $44.02 million. As a group, research analysts forecast that Treace Medical Concepts, Inc. will post -0.83 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on TMCI shares. Truist Financial increased their price objective on shares of Treace Medical Concepts from $4.00 to $5.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. Wall Street Zen raised shares of Treace Medical Concepts from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Finally, Weiss Ratings lowered Treace Medical Concepts from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $5.17.

Institutional Trading of Treace Medical Concepts

A number of institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC acquired a new stake in shares of Treace Medical Concepts in the first quarter valued at about $701,000. Weber Capital Management LLC ADV acquired a new position in Treace Medical Concepts during the fourth quarter valued at approximately $1,445,000. GSA Capital Partners LLP boosted its position in Treace Medical Concepts by 212.5% during the fourth quarter. GSA Capital Partners LLP now owns 347,755 shares of the company’s stock valued at $852,000 after purchasing an additional 236,477 shares during the last quarter. Gagnon Advisors LLC grew its stake in Treace Medical Concepts by 58.4% in the fourth quarter. Gagnon Advisors LLC now owns 1,534,034 shares of the company’s stock valued at $3,758,000 after purchasing an additional 565,570 shares in the last quarter. Finally, Gagnon Securities LLC grew its stake in Treace Medical Concepts by 37.7% in the fourth quarter. Gagnon Securities LLC now owns 3,110,575 shares of the company’s stock valued at $7,621,000 after purchasing an additional 852,337 shares in the last quarter. Institutional investors own 84.08% of the company’s stock.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.